from Jules: of note, there were several studies reported at EASL finding that in patients with cirrhosis before they started treatment for HBV & there was a study in HCV as well which I put right below, listed first, in these patients with cirrhosis despite successful treatment there is a risk for developing HCC, liver cancer, meaning undue delay of treatment may encourage a risk for HCC, liver cancer, if one develops cirrhosis before starting therapy; biopsy and non-invasive tests are not always accurate, so one might have undetected cirrhosis even if the test says stage 2. Granted, in HCV achieving SVR minimizes that risk but it doesnt eliminate the risk. In HBV read the Greek study below & “Long-Term Tenofovir Fumarate (TDF) Therapy and the Risk for Hepatocellular Carcinoma", there were several similar additional studies at EASL.